UroGen Pharma Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 20.85 million compared to USD 16.1 million a year ago. Net loss was USD 21.88 million compared to USD 25.83 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 1.13 a year ago.
For the nine months, sales was USD 59.18 million compared to USD 46.27 million a year ago. Net loss was USD 76.23 million compared to USD 80.91 million a year ago. Basic loss per share from continuing operations was USD 2.89 compared to USD 3.56 a year ago.